Bernstein Liebhard LLP reminds Regeneron Pharmaceuticals investors that the deadline to join a securities fraud class action lawsuit is September 14, 2026. The lawsuit, filed on behalf of those who purchased or acquired Regeneron common stock between August 1, 2025 and May 15, 2026, alleges the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices and resulting in significant investor losses when the truth emerged. Investors who wish to serve as lead plaintiff must file papers by the September 14 deadline, though participation in any recovery does not require serving in that role. Bernstein Liebhard LLP, which has recovered over $3.5 billion for clients since 1993, is handling the case on a contingency fee basis with no upfront costs to shareholders.
Regeneron Pharmaceuticals IncSecurities fraud class action lawsuit alleges false statements, causing artificial inflation and investor losses.